newsfilter

$ASTX News

Last published 5y ago

  • 5y agoATHXBITIASTXAthersys Announces CEO TransitionBusiness WireCLEVELAND, Ohio--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Company’s President and Chief Operating Officer, as Interim Chief Executive Officer ...
  • 13y agoASTXLaw Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Astex Pharmaceuticals, Inc. ShareholdersBusiness WireNEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of Astex Pharmaceuticals, Inc. (“Astex” or the “Company”) (NASDAQ:ASTX) related to the proposed acquisition of the Company by Otsuka Pharmaceutical Co., Ltd. (“Otsuka”). Under the terms of the transaction, Astex shareholders will receive $8.50 in cash for each share of Astex owned, valui ...
  • 13y agoASTXM & A Attorneys At Rigrodsky & Long, P.A. Announce Investigation Of Possible Inadequately Priced Astex Pharmaceuticals, Inc. BuyoutBusiness WireWILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Astex Pharmaceuticals, Inc. (“Astex” or the “Company”) (NASDAQ GS: ASTX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Otsuka Pharmaceutical Co., Ltd. (“ ...
  • 13y agoASTXLaw Firm Brower Piven Announces Investigation of Astex Pharmaceuticals, Inc. Proposed AcquisitionBusiness WireSTEVENSON, Md.--(BUSINESS WIRE)--The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Astex Pharmaceuticals, Inc. (“Astex”) (NASDAQ GS: ASTX) and other violations of state law by the board of directors of Astex relating to the proposed acquisition of the Company by Otsuka Pharm ...
  • 13y agoASTXKomlossy Law, P.A. Announces Investigation of Astex Pharmaceuticals, Inc.Business WireHOLLYWOOD, Fla.--(BUSINESS WIRE)--Komlossy Law, P.A. is investigating the Board of Directors of Astex Pharmaceuticals, Inc. (“Astex”) or the “Company”) (NASDAQ:ASTX) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to complete a sale of the Company to Otsuka Pharmaceutical ("Otsuka") in a transaction valued at approximately $886 million. Pu ...
  • 13y agoASTXFinkelstein Thompson LLP Announces Investigation of Astex Pharmaceuticals, Inc. BuyoutBusiness WireWASHINGTON--(BUSINESS WIRE)--The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) (“Astex” or “the Company”), concerning the Company’s proposed acquisition by Otsuka Holdings Co., Ltd. (TYO: 45780) (“Otsuka”). Under the terms of the merger agreement, Astex shareholders will receive $8.50 in cash for each ...
  • 13y agoASTXNewman Ferrara LLP Announces Investigation of Astex Pharmaceutics, Inc.Business WireNEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP is investigating potential claims against the board of directors of Astex Pharmaceuticals, Inc. (“Astex”) (Nasdaq: ASTX) concerning the proposed acquisition of Astex by Otsuka Pharmaceutical Co.
  • 13y agoASTXRigrodsky & Long, P.A. Announces Investigation Of Astex Pharmaceuticals, Inc. BuyoutBusiness WireWILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A.:
  • 14y agoASTXAstex Pharmaceuticals to Present at AACR Annual MeetingBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of fourteen abstracts for presentation at the American Association for Cancer Research (AACR) 2012 Annual Meeting. Oral and poster presentations will occur on March 31, April 1-3 in Chic ...
  • 14y agoASTXAstex Pharmaceuticals Announces March 27th Analyst and Investor Day AgendaBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the Agenda for its Annual Analyst and Investor Day webcast, to take place from 10 am to 12 pm ET on Tuesday, March 27th in New York.
  • 14y agoASTXEisai Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Dacogen® (decitabine) for Injection sNDA in Acute Myeloid LeukemiaBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter to partner Eisai for their supplemental New Drug Application (sNDA) for Dacogen® (decitabine) for Injection for patients with acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for ...
  • 14y agoASTXAstex Pharmaceuticals Reports 2011 Fourth Quarter and Year-End Financial ResultsBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), today reported financial results for the fourth quarter and year ended December 31, 2011.
  • 14y agoASTXAstex Pharmaceuticals to Announce 2011 Fourth Quarter and Year-End Financial Results on March 5, 2012Business WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that it will release its 2011 fourth quarter and fiscal year-end results on Monday, March 5, 2012. James S.J. Manuso, PhD, chairman and chief executive officer, and the Astex Pharmaceuticals management ...
  • 14y agoASTXAstex Pharmaceuticals to Host Annual Analyst and Investor Day on March 27, 2012Business WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced its Annual Analyst and Investor Day will take place from 10 am to 1 pm ET on Tuesday, March 27th in New York.
  • 14y agoASTXFDA’s Oncologic Drugs Advisory Committee (ODAC) Votes to not Support Benefit/Risk Profile of DACOGEN® (decitabine) in Acute Myeloid LeukemiaBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) today announced that the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 3 with one person abstaining that data in our partner Eisai’s supplemental new Drug Application (sNDA) for DACOGEN® (decitabine) for Injection did not support a favorable benefit-risk profile for the tr ...
  • 14y agoASTXAstex Pharmaceuticals Announces Presentations at Upcoming ConferencesBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that James S.J. Manuso, PhD, chairman and chief executive officer, will present at the following conferences:
  • 14y agoASTXAstex Announces Early Transfer of Epigenetics Project to GSKBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) today announced that the multi-year collaboration to discover cancer therapeutics based on epigenetic targets entered into by SuperGen, Inc. and GlaxoSmithKline (GSK) in November 2009 is terminating and existing research work and assets generated under the CLIMB™ epigenetic collaboration will be transferred to GSK. Astex w ...
  • 14y agoASTXAstex Pharmaceuticals to Present at Biotech Showcase on January 9thBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel therapeutics, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, will present at Biotech Showcase 2012 on Monday, January 9th in San Francisco.
  • 14y agoASTXAstex Announces FDA ODAC Meeting of sNDA Application for Dacogen in Treatment of Elderly AMLBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), today announced the pre-publication notice of the Food and Drug Administration (FDA), Oncologic Drugs Advisory Committee (ODAC) Meeting to discuss the supplemental new drug application (sNDA) for Dacogen® (decitabine) for Injection, an application submitted by Eisai, Inc. The proposed indication for this product is for th ...
  • 14y agoASTXAstex Pharmaceuticals to Present at World Epigenetics Summit on December 8thBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel therapeutics, today announced that Tom Heightman, Ph.D., director, medicinal chemistry, will co-chair and present at the 2nd World Epigenetics Summit: Unlocking the Commercial and Therapeutic Potential of Epigenetics Research on December 6 to 8, ...
  • 14y agoASTXAstex Pharmaceuticals to Present at Piper Jaffray Health Care Conference on November 29thBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel therapeutics, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, and Mohammad Azab, M.D., chief medical officer, will present at the 23rd Annual Piper Jaffray Health Care Conference on Tuesday, November 29th in N ...
  • 15y agoASTXAstex Pharmaceuticals to Present at Lazard Healthcare Conference on November 16thBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel therapeutics, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, and Martin Buckland, D.Phil., chief business officer, will present at the Lazard Capital Markets 8th Annual Healthcare Conference on Wednesday, Nov ...
  • 15y agoASTXAstex Pharmaceuticals to Present at AACR-NCI-EORTCBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel therapeutics, announced the acceptance of four abstracts detailing recent work with Astex Pharmaceuticals compounds. Poster presentations will occur on November 13, 14 and 15, 2011 at the 2011 AACR-NCI-EORTC International Conference on Molecular ...
  • 15y agoASTXAstex Pharmaceuticals Reports 2011 Third Quarter Financial ResultsBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), formerly SuperGen, Inc., today reported financial results for the third quarter ended September 30, 2011. The Company reported a net loss for the 2011 third quarter of $1.1 million, or $0.01 per basic and diluted share, compared with net income of $3.9 million, or $0.06 per basic and diluted share, for the same prior year ...
  • 15y agoASTXAstex Pharmaceuticals to Present a Novel Targeted Approach to the Treatment of HCV at the AASLD MeetingBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics, announced that it will present data on its novel, first-in-class direct acting antiviral agents (DAA) against Hepatitis C Virus (HCV) at the 62nd Annual Meeting of the American Association for the Study of Liver Di ...
  • 15y agoASTXAstex Pharmaceuticals to Announce 2011 Third Quarter Financial Results on October 31, 2011Business WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery, development and commercialization of novel cancer therapies, announced that it will release its 2011 third quarter financial results on Monday, October 31, 2011. James S.J. Manuso, Ph.D., chairman and chief executive officer, and the Astex Pharmaceuticals management team ...
  • 15y agoASTXAstex Pharmaceuticals to Present at BIO Investor Forum on October 26thBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery, development and commercialization of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, will present at the 10th Annual BIO Investor Forum on Wednesday, October 26th in San Francisco.
  • 15y agoASTXAstex Pharmaceuticals to Present at NewsMakers in the Biotech Industry on October 21stBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery, development and commercialization of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, will present at the 18th Annual NewsMakers in the Biotech Industry conference on Friday, October 21st in New York.
  • 15y agoASTXEvidence of AT13387 Activity in Gastrointestinal Stromal Tumor Models Presented at ECCOBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that preclinical data demonstrating that AT13387, a novel non-ansamycin Heat Shock Protein 90 (HSP90) inhibitor, is active in in vitro gastrointestinal stromal tumor (GIST) models (Abstract #9407) was presented at the ...
  • 15y agoASTXAstex Pharmaceuticals to Present at Jefferies Global Healthcare Conference on September 27thBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that Harren Jhoti, Ph.D., president, will present at the Jefferies 2011 Global Healthcare Conference on Tuesday, September 27th in London.
  • 15y agoASTXAstex Pharmaceuticals to Present at UBS Global Life Sciences Conference on September 21stBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., chairman and chief executive officer, and Mohammad Azab, M.D., chief medical officer, will present at the UBS Global Life Sciences Conference on Wednesday, September 21st in New York ...
  • 15y agoASTXSuperGen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol and New WebsiteBusiness WireDUBLIN, Calif.--(BUSINESS WIRE)--SuperGen, Inc. (NASDAQ:ASTX) announced that it has officially begun operating under the name Astex Pharmaceuticals, Inc. Concurrent with this new name, and effective at the start of trading today, September 12, 2011, the ticker symbol for the Company’s common stock listed on NASDAQ has changed from "SUPG" to "ASTX."